Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | DCEP and bendamustine/prednisone as salvage for refractory MM

Ravi Vij • 5 Apr 2020
Multiple Myeloma Antibodies bb2121 Bendamustine CAR-T Cisplatin Cyclophosphamide Dexamethasone Etoposide Prednisone Selinexor
DREAMM-2

Ravi Vij, MD, MBA, Washington University Medical School, St Louis, MO, outlines the use of dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma (MM). Dr Vij goes on to discuss the choice between an antibody-drug conjugate, or CAR-T cell therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ravi Vij

2:48
MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma
Ravi Vij • 11 Dec 2023
2:26
Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma
Ravi Vij • 11 Dec 2023
3:23
Updated safety and efficacy results of Abbv-383, a novel BsAb, in patients with R/R multiple myeloma
Ravi Vij • 11 Dec 2023
2:35
Resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
Ravi Vij • 12 Dec 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals